Windtree Therapeutics has announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, to bolster its balance sheet. Following a recent all-time high for BNB, the Pennsylvania-based biotech firm revealed it would raise $520 million specifically for these acquisitions after initial plans for a $200 million buy. The funding will come from a $500 million equity line of credit with an unnamed institutional investor and a $20 million agreement with Build and Build Corp. CEO Jed Latkin emphasized that stockholder approval for this strategy is crucial. Windtree's move aligns with a growing trend of companies incorporating significant cryptocurrency holdings, following examples like Strategy's Bitcoin investments. Though Windtree's stock experienced a slight decline recently, it has seen a remarkable 162% increase over the past month. BNB, launched by Binance in 2017, recently traded at $769 and faced fluctuations after reaching an all-time high of $808. Windtree is among multiple firms building crypto treasuries, highlighting the increasing institutional interest in digital assets.

Source 🔗